Download full-text PDF |
Source |
---|
Clin Transl Gastroenterol
January 2025
Division of Pediatric Gastroenterology and Nutrition, Department of Pediatrics, University of Alberta, Edmonton, Alberta, Canada.
Background: Neutrophil-to-lymphocyte ratio (NLR) is a novel biomarker studied in several autoimmune diseases including inflammatory bowel diseases (IBD) in adults, but poorly characterized in pediatric IBD (pIBD). We aimed to primarily investigate the relationship between NLR and pIBD endoscopic disease severity. We also examined whether NLR predicted hospitalization, surgery, and therapy response by 52 weeks.
View Article and Find Full Text PDFLower gastrointestinal bleeding (LGIB) is a challenging and potentially life-threatening medical condition that often necessitates prompt intervention. In the quest to improve patient outcomes, one therapeutic agent has garnered significant attention - tranexamic acid (TXA). The basic aim of the study is to systematically review the role of TXA in LGIB.
View Article and Find Full Text PDFArch Dis Child
January 2025
Paediatric Liver, GI and Nutrition Centre, King's College Hospital, London, UK.
Alcohol Alcohol
January 2025
Subdivision of Gastroenterology and Hepatology, 5th Department of Internal Medicine, Comenius University Faculty of Medicine, University Hospital Bratislava, Ružinovská 6, 826 06, Bratislava, Slovakia.
Background And Aims: Alcohol-associated hepatitis (AH) frequently triggers acute decompensation (AD) in cirrhosis, with severe AH linked to high short-term mortality, especially in acute-on-chronic liver failure. Current corticosteroid treatments have limited efficacy, highlighting the need for new therapies. We hypothesized that severe AH outcomes are influenced by early specialized care; thus, we examined the impact of time-to-tertiary care (TTTc).
View Article and Find Full Text PDFJ Crohns Colitis
January 2025
IRCCS Hospital San Raffaele and University Vita-Salute San Raffaele, Gastroenterology and Endoscopy, Milan, Italy.
Background: Intestinal ultrasound (IUS) is emerging as a valuable tool to assess treatment response in inflammatory bowel disease (IBD) clinical trials. This study details how IUS defines response and remission to evaluate treatment efficacy in IBD patients.
Methods: We conducted a comprehensive search of studies from 1984 to 31 March 2024, focusing on IUS use in assessing treatment efficacy in IBD.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!